Literature DB >> 20393008

SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.

Kei Miyoshi1, Norihiro Sato, Kenoki Ohuchida, Kazuhiro Mizumoto, Masao Tanaka.   

Abstract

BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC) is a protein which governs diverse cellular functions and matrix remodeling systems. It was reported that SPARC expression of peritumoral fibroblasts was correlated with poor prognosis in resectable pancreatic cancer patients in immunohistochemical analysis. However, the significance of SPARC mRNA expression in pancreatic adenocarcinoma remains unclear.
MATERIALS AND METHODS: SPARC mRNA expression was evaluated in 104 formalin-fixed paraffin-embedded tissue samples of pancreatic adenocarcinoma patients with macro-dissection technique.
RESULTS: High SPARC mRNA expression was associated with a poorer prognosis than low SPARC. In univariate Cox's proportion hazard model, depth of tumor invasion, lymph node metastasis, histopathological tumor grade, lymphatic invasion, vascular invasion, surgical margin, no chemotherapy and high SPARC expression were significant prognostic factors. In multivariate analysis, histopathological tumor grade, surgical margin, no chemotherapy and high SPARC expression were independent significant prognostic factors.
CONCLUSION: SPARC mRNA expression is a prognostic marker for pancreatic adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393008

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

Review 3.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

Review 4.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 5.  Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

Authors:  Thomas S Frank; Xiaotian Sun; Yuqing Zhang; Jingxuan Yang; William E Fisher; Marie-Claude Gingras; Min Li
Journal:  Cancer Lett       Date:  2015-04-15       Impact factor: 8.679

6.  Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.

Authors:  Maria Celeste Palmarocchi; Ruben Carlo Balzarotti Canger; Piercarlo Saletti
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

Review 7.  Molecular targeted approaches for treatment of pancreatic cancer.

Authors:  Z Q Huang; A K Saluja; V Dudeja; S M Vickers; D J Buchsbaum
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 8.  Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?

Authors:  Chen Liang; Si Shi; Qingcai Meng; Dingkong Liang; Shunrong Ji; Bo Zhang; Yi Qin; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  Cell Mol Life Sci       Date:  2017-10-09       Impact factor: 9.261

9.  Novel role for matricellular proteins in the regulation of islet β cell survival: the effect of SPARC on survival, proliferation, and signaling.

Authors:  Claire L Ryall; Katrina Viloria; Fadel Lhaf; Anthony J Walker; Aileen King; Peter Jones; David Mackintosh; Rosemary McNeice; Hemant Kocher; Malin Flodstrom-Tullberg; Charlotte Edling; Natasha J Hill
Journal:  J Biol Chem       Date:  2014-09-09       Impact factor: 5.157

10.  SPARC expression and prognostic value in non-small cell lung cancer.

Authors:  Yan Huang; Jing Zhang; Yuan-Yuan Zhao; Wei Jiang; Cong Xue; Fei Xu; Hong-Yun Zhao; Yang Zhang; Li-Ping Zhao; Zhi-Huang Hu; Zhi-Wen Yao; Qian-Yong Liu; Li Zhang
Journal:  Chin J Cancer       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.